NO20042272L - Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister - Google Patents

Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister

Info

Publication number
NO20042272L
NO20042272L NO20042272A NO20042272A NO20042272L NO 20042272 L NO20042272 L NO 20042272L NO 20042272 A NO20042272 A NO 20042272A NO 20042272 A NO20042272 A NO 20042272A NO 20042272 L NO20042272 L NO 20042272L
Authority
NO
Norway
Prior art keywords
administering
methods
pharmaceutical compositions
selective agonists
receptor selective
Prior art date
Application number
NO20042272A
Other languages
English (en)
Norwegian (no)
Inventor
David Duane Thompson
Jinyang Hong
Yesook Kim
Francis Dumont
Richard Wilker Korsmeyer
Mei Li
Vishwas Madhaw Paralkar
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20042272L publication Critical patent/NO20042272L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042272A 2001-11-30 2004-06-01 Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister NO20042272L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33515601P 2001-11-30 2001-11-30
PCT/IB2002/004368 WO2003045371A1 (en) 2001-11-30 2002-10-21 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists

Publications (1)

Publication Number Publication Date
NO20042272L true NO20042272L (no) 2004-07-28

Family

ID=23310510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042272A NO20042272L (no) 2001-11-30 2004-06-01 Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister

Country Status (25)

Country Link
US (1) US20030166631A1 (pl)
EP (1) EP1448182A1 (pl)
JP (1) JP2005513030A (pl)
KR (1) KR20040063981A (pl)
CN (1) CN1599605A (pl)
AR (1) AR037593A1 (pl)
AU (1) AU2002348948A1 (pl)
BR (1) BR0214614A (pl)
CA (1) CA2468494A1 (pl)
GT (1) GT200200235A (pl)
HN (1) HN2002000336A (pl)
IL (1) IL161834A0 (pl)
MX (1) MXPA04003689A (pl)
NO (1) NO20042272L (pl)
NZ (1) NZ532209A (pl)
PA (1) PA8559601A1 (pl)
PE (1) PE20030660A1 (pl)
PL (1) PL370914A1 (pl)
PY (1) PY0228253A (pl)
RU (1) RU2004116318A (pl)
SV (1) SV2004001417A (pl)
TW (1) TW200300342A (pl)
UY (1) UY27556A1 (pl)
WO (1) WO2003045371A1 (pl)
ZA (1) ZA200402795B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP2422814A1 (en) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
EP1996118A4 (en) * 2006-03-07 2013-03-06 Osteoscreen Ip Llc STRENGTHENING BONES AND CARTILES BY HMG-CO-A REDUCTASE INHIBITOR
AU2007280130B2 (en) * 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
EP2195656A4 (en) * 2007-08-21 2011-10-19 Senomyx Inc HUMAN T2R BITTERITY RECEPTORS AND USES THEREOF
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
FR3034678A1 (fr) * 2015-04-07 2016-10-14 Geocorail Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre.
IL261002B2 (en) * 2016-02-12 2024-07-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CA3134674A1 (en) * 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
WO2021163400A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
ES2303341T3 (es) * 1996-12-20 2008-08-01 Pfizer Inc. Prevencion y tratamiento de trastorno del esqueleto con agonistas de la prostaglandina e2 selectivos del subtipo de receptor ep2.
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists

Also Published As

Publication number Publication date
NZ532209A (en) 2007-05-31
SV2004001417A (es) 2004-02-24
CA2468494A1 (en) 2003-06-05
ZA200402795B (en) 2005-04-13
JP2005513030A (ja) 2005-05-12
EP1448182A1 (en) 2004-08-25
AU2002348948A1 (en) 2003-06-10
PL370914A1 (pl) 2005-06-13
GT200200235A (es) 2003-06-25
MXPA04003689A (es) 2004-07-23
US20030166631A1 (en) 2003-09-04
HN2002000336A (es) 2003-02-10
IL161834A0 (en) 2005-11-20
BR0214614A (pt) 2004-09-14
PY0228253A (es) 2004-06-01
KR20040063981A (ko) 2004-07-15
RU2004116318A (ru) 2005-03-27
AR037593A1 (es) 2004-11-17
UY27556A1 (es) 2003-06-30
CN1599605A (zh) 2005-03-23
TW200300342A (en) 2003-06-01
PA8559601A1 (es) 2003-07-28
WO2003045371A1 (en) 2003-06-05
PE20030660A1 (es) 2003-08-04

Similar Documents

Publication Publication Date Title
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
EP1513825A4 (en) ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
IS7735A (is) Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
IS6811A (is) Lyfjafræðilegar samsetningar NMDA viðtakagerandefna
HUP0400194A3 (en) Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20054944D0 (no) Cladribinformuleringer for forbedret oral og transmuskos administrering
DK1495023T3 (da) Hidtil ukendte derivater af 1,2,3-substitueret indolizin, FGF-inhibitorer, fremgangsmåde for fremstilling og farmaceutiske sammensætninger indeholdende disse
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
EP1501352A4 (en) METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application